CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Apotex Corp.

1:15-cv-00044

Overview

Case Number 1:15-cv-00044
Filing Date 2015-01-15
Status Terminated
Termination Date 2015-03-24
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 28:1331 Fed. Question
Jury Demand None

Parties

Defendant

Apotex Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Apotex Corp. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Sanofi Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Aventis Pharma S.A. NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Sanofi-Aventis U.S. LLC Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 9 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 4 proceedings
πŸ›οΈ
USPTO PTAB Trials 2 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (9): FR πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 2 U.S. Courts: 4
USPTO PTAB Trial 2018-10-31
IPR2019-00136

Neptune Generics, LLC et al. v. Aventis Pharma S.A. et al.

U.S. Continuation Sibling (5847170)
Status: Institution Denied
USPTO PTAB Trial 2016-02-17
IPR2016-00627

Mylan Laboratories Limited et al. v. Aventis Pharma S.A. et al.

U.S. Continuation Sibling (5847170)
Status: Institution Denied
U.S. District Court 2015-05-15
3:15-cv-03392

SANOFI-AVENTIS U.S. LLC v. MYLAN LABORATORIES LIMITED

U.S. Family Sibling (["US5847170"])
Status: NJD
U.S. District Court 2014-12-30
1:14-cv-01533

Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA LLC

Asserted Patent
Status: DED
U.S. District Court 2014-12-29
3:14-cv-08079

SANOFI-AVENTIS U.S. LLC v. ACCORD HEALTHCARE, INC.

Asserted Patent
Status: NJD
U.S. District Court 2014-12-29
3:14-cv-08082

SANOFI-AVENTIS U.S. LLC v. FRESENIUS KABI USA, LLC

Asserted Patent
Status: NJD
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5847170
Taxoids, their preparation and pharmaceutical compositions containing them
Filed: 1996-03-26
Issued: 1998-12-08
Expired (Term Ended) +1826d PTA
Expires: 2021-03-26
US7241907
Acetone solvate of dimethoxy docetaxel and its process of preparation
Filed: 2004-09-17
Issued: 2007-07-10
Expired (Term Ended) +449d PTA
Expires: 2025-12-10

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1826 days) / Cellect Scrutiny β€” Over 1826 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(10 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Apotex Corp., Apotex Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1656928.) - filed by Sanofi-Aventis U.S. LLC, Aventis Pharma S.A., Sanofi. (Attachments: # 1 Exhibit A & B, # 2 Civil Cover Sheet)(etg, ) (Entered: 01/16/2015)

Entry #1 • 2015-01-15
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (etg, ) (Entered: 01/16/2015)

Entry #2 • 2015-01-15
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/05/14. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 12/17/2017. (etg, ) (Entered: 01/16/2015)

Entry #3 • 2015-01-15
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,847,170; 7,241,907 B2. (etg, ) (Entered: 01/16/2015)

Entry #4 • 2015-01-15
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aventis Inc., Corporate Parent Sanofi US Services Inc., Corporate Parent Sanofi, Corporate Parent sanofi-aventis Amerique du Nord for Sanofi-Aventis U.S. LLC; Corporate Parent Aventis Inc., Corporate Parent Sanofi, Corporate Parent sanofi-aventis Amerique du Nord for Aventis Pharma S.A. filed by Aventis Pharma S.A., Sanofi, Sanofi-Aventis U.S. LLC. (etg, ) (Entered: 01/16/2015)

Entry #5 • 2015-01-15
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc